Please assess the completion status of the following clinical trial:

Trial Title: A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
The following subjects were eligible for randomization:~1. men or women ≥ 20 years of age at screening. Women of childbearing potential must test negative by urine pregnancy test.~2. were treatment naïve or taking one oral anti-diabetic medication in combination with diet and exercise~3. were diagnosed with T2DM with HbA1c levels at screening between 7.0% and 8.5% (inclusive) if treatment naïve or with HbA1c levels between 6.5 and 8.5% (inclusive) if on one oral anti-diabetic medication~4. had a body mass index (BMI) ≤ 40 kg/m2~5. were taking stable doses of medication for hypertension or hyperlipidemia that has not changed for at least 30 days prior to screening (if applicable)~6. were able to comprehend the study participation requirements and willing to provide written informed consent in accordance with institutional and regulatory guidelines~7. were able to maintain adequate glycemic control at the run-in visit (for subjects who complete the washout)~8. had an HbA1c between 7.0 and 8.5% (inclusive) prior to randomization (day -3 to -5)~9. were capable of adhering to the investigational product administration requirements as evidenced by omission of no more than one dose of run-in medication~Subjects who exhibited any of the following characteristics were to be ineligible for randomization:~1. Diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young~2. Used parenteral therapy for treatment of diabetes~3. Pregnancy or current breastfeeding status~4. Hemoglobinopathy or carrier status for hemoglobin alleles that affect HbA1c measurement~5. Genitourinary tract infection within 6 weeks of screening or history of ≥3 genitourinary infections requiring treatment within 6 months of screening~6. Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 at screening.~7. Uncontrolled hypertension at screening~8. A positive result on hepatitis B surface antigen, hepatitis C, or positive result from screen for drugs of abuse~9. History of human immunodeficiency virus infection~10. Life expectancy \< 2 years~11. History of New York Heart Association Class 4 heart failure within 3 months of screening~12. History of myocardial infarction, unstable angina, stroke, or hospitalization for heart failure within 3 months of screening~13. History of treatment with an investigational drug within 30 days or within 7 half lives of the investigational drug, whichever is longer~14. Previous treatment with bexagliflozin~15. Had taken or within 6 months of taking any Sodium Glucose Transporter 2 (SGLT2) inhibitors prior to screening~16. Participation of another interventional trial~17. Not able to comply with the study scheduled visits~18. Affected by any condition, disease, disorder, or clinically relevant abnormality that, in the opinion of the investigator, would jeopardize the subject's appropriate participation in this study.~19. Liver function tests resulting in Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 2.5 x upper limit of normal (ULN) or total bilirubin ≥ 1.5 x ULN, with the exception of isolated Gilbert's syndrome ,at screening~20. Exhibited fasting plasma glucose ≥ 250 mg/dL (13.9 mmol/L) on two or more consecutive days prior to randomization or exhibited severe clinical signs or symptoms of hyperglycemia during the washout or run-in periods, including weight loss, blurred vision, increased thirst, or increased urination, or fatigue~21. Fasting Plasma Glucose ≥ 250 mg/dL at randomization~22. Prior renal transplantation or evidence of nephrotic syndrome, defined as a urine albumin-to-creatinine ratio (UACR) \> 2000 mg/g at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bexagliflozin tablets, 5 mg (Type: ACTIVE_COMPARATOR): Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
- Bexagliflozin tablets, 10 mg (Type: ACTIVE_COMPARATOR): Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
- Bexagliflozin tablets, 20 mg (Type: ACTIVE_COMPARATOR): Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
- Bexagliflozin tablets, placebo (Type: PLACEBO_COMPARATOR): Bexagliflozin tablets, placebo, once daily by mouth before breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete